Skip to main content

Table 4 Patient demographics for OCEAN and selected randomized controlled trials in the indication retinal vein occlusion

From: Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

Study Treatment group N Age mean ± SD (years) Age range (years) Gender, n (%) Time since first diagnosis of RVO mean ± SD (months) Time since first diagnosis of RVO median [range] (months) Baseline VA
male female ETDRS letters analogue (mean ± SD)a
Indication BRVO
 OCEANb BRVO patients Ranibizumab 0.5 mg 204 71.2 ± 10.0 39.2-92.7 85 (41.7) 119 (58.3) 6.30 ± 16.35 c,d 1.63 [0–127] c,d 55.9 ± 20.9
 BRAVO [50] Sham injections (6 months) 132 65.2 ± 12.7 26-89 74 (56.1) 58 (43.9) 3.7 ± 3.7 2 [0–16] 54.7 ± 12.2
Ranibizumab 0.3 mg 134 66.6 ± 11.2 43-90 67 (50.0) 67 (50.0) 3.6 ± 4.1 2 [0–35] 56.0 ± 12.1
Ranibizumab 0.5 mg 131 67.5 ± 11.8 41-91 71 (54.2) 60 (45.8) 3.3 ± 3.1 2 [0–13] 53.0 ± 12.5
 VIBRANT [51] Laser 90 63.9 ± 11.4 n. a. n. a. 36 (40.0) 1.4 ± 1.3 d n. a. 57.7 ± 11.3
Aflibercept 2 mg 91 67.0 ± 10.4 n. a. n. a. 47 (51.6) 1.4 ± 1.4 d n. a. 58.6 ± 11.4
Indication CRVO
 OCEANb CRVO patients Ranibizumab 0.5 mg 121 70.3 ± 11.5 26.7-91.9 57 (47.1) 64 (52.9) 3.78 ± 6.49 c,d 1.44 [0–38] c,d 43.7 ± 25.0
 CRUISE [52] Sham injections 130 65.4 ± 13.1 20-91 72 (55.4) 58 (44.6) 2.9 ± 2.9 2 [0–14] 49.2 ± 14.7
Ranibizumab 0.3 mg 132 69.7 ± 11.6 38-90 71 (53.8) 61 (46.2) 3.6 ± 3.2 2 [0–12] 47.4 ± 14.8
Ranibizumab 0.5 mg 130 67.6 ± 12.4 40-91 80 (61.5) 50 (38.5) 3.3 ± 3.7 2 [0–27] 48.1 ± 14.6
 COPERNICUS [53]e Aflibercept 2 mg 2q4, then PRN 114 65.5 ± 13.57 n. a. 69 (61) 45 (39) 2.73 ± 3.09 n. a. 50.7 ± 13.9
Sham injections 2q4, then Aflibercept 2 mg PRN 73 67.5 ± 14.29 n. a. 38 (52) 35 (48) 1.88 ± 2.19 n. a. 48.9 ± 14.4
 GALILEO [54] VEGF Trap-Eye (Aflibercept) 2q4 103 59.9 ± 12.4 n. a. 58 (56.3) 45 (43.7) 2.6 ± 2.9d n. a. 53.6 ± 15.8
Sham injections 68 63.8 ± 13.3 n. a. 37 (54.4) 31 (45.6) 2.9 ± 2.6d n. a. 50.9 ± 15.4
  1. aMethod of measuring baseline VA not always explained in sources. Direct comparisons of VA results may not be reliable
  2. bMissing values in OCEAN: time since first diagnosis of RVO: 3 in BRVO, 3 in CRVO; baseline VA: 1 in BRVO, 3 in CRVO
  3. cTime since diagnosis until first injection in OCEAN
  4. dResults converted to months (originally in days)
  5. eMissing values in COPERNICUS: Time since first diagnosis of RVO: 1 patient (in treatment group “Aflibercept 2 mg 2q4, then PRN”)
  6. Abbreviations: 2q4: every 4 weeks for 24 weeks; BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; ETDRS: Early Treatment Diabetic Retinopathy Study; N: total number of patients; n: number of patients; n. a.: data not available in source; PRN: pro re nata (as needed); RVO: retinal vein occlusion; SD: standard deviation; VA: visual acuity